{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:34:42Z","timestamp":1794346482868,"version":"4.9.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Natural killer (NK) cells have evolved to detect abnormalities in tissues arising from infection with pathogens, genomic damage, or transformation and respond rapidly to the production of potent proinflammatory and cytolytic mediators. While this acute proinflammatory response is highly efficient at orchestrating sterilizing immunity to pathogens in a matter of days, cellular transformation often avoids the innate detection mechanisms of NK cells. When cellular transformation results in malignancy, tumor cells and\/or the tumor microenvironment can evolve additional mechanisms to circumvent NK cell responses, and cancer is now a dominant disease burden worldwide. Here, we review recent advances in our understanding of the combined relationship between malignancies and natural killer (NK) cells, learn from recent clinical efforts in therapeutically targeting natural killer (NK) cells in cancer and outline some emerging therapeutic concepts that aim to improve the innate immune response against cancer.<\/jats:p>","DOI":"10.1038\/s41423-025-01297-4","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T10:04:51Z","timestamp":1747994691000},"page":"699-711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Adjusting the scope of natural killer cells in cancer therapy"],"prefix":"10.1038","volume":"22","author":[{"given":"Zihen","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangpeng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-9966","authenticated-orcid":false,"given":"Jai","family":"Rautela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8812-2763","authenticated-orcid":false,"given":"Michael","family":"Chopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5267-7211","authenticated-orcid":false,"given":"Nicholas D.","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"1297_CR1","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652\u201369.","journal-title":"Cell"},{"key":"1297_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2024.04.003","volume":"10","author":"M Julve","year":"2024","unstructured":"Julve M, Lythgoe MP, Larkin J, Furness AJS. Lifileucel: the first cellular therapy approved for solid tumors. Trends Cancer Res. 2024;10:475\u20137.","journal-title":"Trends Cancer Res"},{"key":"1297_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomized, phase 2b study. Lancet. 2024;403:632\u201344.","journal-title":"Lancet"},{"key":"1297_CR4","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/bloodadvances.2021004535","volume":"8","author":"JE Haydu","year":"2024","unstructured":"Haydu JE, Abramson JS. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Adv. 2024;8:4700\u201310.","journal-title":"Blood Adv"},{"key":"1297_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","volume":"20","author":"ND Huntington","year":"2020","unstructured":"Huntington ND, Cursons J, Rautela J. The cancer\u2013natural killer cell immunity cycle. Nat Rev Cancer. 2020;20:437\u201354.","journal-title":"Nat Rev Cancer"},{"key":"1297_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0952-7915(98)80163-5","volume":"10","author":"H Okamura","year":"1998","unstructured":"Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol. 1998;10:259\u201364.","journal-title":"Curr Opin Immunol"},{"key":"1297_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","volume":"31","author":"DH Raulet","year":"2013","unstructured":"Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013;31:413\u201341.","journal-title":"Annu Rev Immunol"},{"key":"1297_CR8","doi-asserted-by":"publisher","first-page":"eadn9879","DOI":"10.1126\/sciimmunol.adn9879","volume":"9","author":"F Li","year":"2024","unstructured":"Li F, Yang Z, Savage TM, Vincent RL, de Los Santos-Alexis K, Ahn A, et al. Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms. Sci Immunol. 2024;9:eadn9879.","journal-title":"Sci Immunol"},{"key":"1297_CR9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17:1025.","journal-title":"Nat Immunol"},{"key":"1297_CR10","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","volume":"356","author":"K Imai","year":"2000","unstructured":"Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795\u20139.","journal-title":"Lancet"},{"key":"1297_CR11","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","volume":"7","author":"J Cursons","year":"2019","unstructured":"Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, Anderson A, Hollande F, Hediyeh-Zadeh S, et al. A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol Res. 2019;7:1162\u201374.","journal-title":"Cancer Immunol Res"},{"key":"1297_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1158\/2326-6066.CIR-21-0137","volume":"9","author":"M Foroutan","year":"2021","unstructured":"Foroutan M, Molania R, Pfefferle A, Behrenbruch C, Scheer S, Kallies A, et al. The Ratio of Exhausted to Resident Infiltrating Lymphocytes Is Prognostic for Colorectal Cancer Patient Outcome. Cancer Immunol Res. 2021;9:1125\u201340.","journal-title":"Cancer Immunol Res"},{"key":"1297_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41:272\u201387.e9.","journal-title":"Cancer Cell"},{"key":"1297_CR14","doi-asserted-by":"publisher","unstructured":"Chan IS, Ewald AJ The changing role of natural killer cells in cancer metastasis. J Clin Invest [Internet]. 2022;132. Available from: https:\/\/doi.org\/10.1172\/JCI143762.","DOI":"10.1172\/JCI143762"},{"key":"1297_CR15","doi-asserted-by":"publisher","unstructured":"Ichise H, Tsukamoto S, Hirashima T, Konishi Y, Oki C, Tsukiji S, et al. Functional visualization of NK cell-mediated killing of metastatic single tumor cells. Elife [Internet]. 2022;11. Available from: https:\/\/doi.org\/10.7554\/eLife.76269.","DOI":"10.7554\/eLife.76269"},{"key":"1297_CR16","doi-asserted-by":"publisher","unstructured":"B\u00f6ttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell [Internet]. 2018;172. Available from: https:\/\/doi.org\/10.1016\/j.cell.2018.01.004.","DOI":"10.1016\/j.cell.2018.01.004"},{"key":"1297_CR17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24:1178\u201391.","journal-title":"Nat Med"},{"key":"1297_CR18","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay S, van der Veen AG, B\u00f6ttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257\u201370.","journal-title":"Cell"},{"key":"1297_CR19","doi-asserted-by":"publisher","first-page":"e2350635","DOI":"10.1002\/eji.202350635","volume":"54","author":"C Patterson","year":"2024","unstructured":"Patterson C, Hazime KS, Zelenay S, Davis DM. Prostaglandin E2 impacts multiple stages of the natural killer cell antitumor immune response. Eur J Immunol. 2024;54:e2350635.","journal-title":"Eur J Immunol"},{"key":"1297_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","volume":"53","author":"E Bonavita","year":"2020","unstructured":"Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity. 2020;53:1215\u201329.e8.","journal-title":"Immunity"},{"key":"1297_CR21","doi-asserted-by":"publisher","first-page":"17460","DOI":"10.1073\/pnas.1904253116","volume":"116","author":"L Schmidt","year":"2019","unstructured":"Schmidt L, Eskiocak B, Kohn R, Dang C, Joshi NS, DuPage M, et al. Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. Proc Natl Acad Sci USA. 2019;116:17460\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1297_CR22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1158\/2326-6066.CIR-21-0587","volume":"10","author":"SS Dinavahi","year":"2022","unstructured":"Dinavahi SS, Chen Y-C, Punnath K, Berg A, Herlyn M, Foroutan M, et al. Targeting WEE1\/AKT restores p53-dependent natural killer-cell activation to induce immune checkpoint blockade responses in \u201ccold\u201d melanoma. Cancer Immunol Res. 2022;10:757\u201369.","journal-title":"Cancer Immunol Res"},{"key":"1297_CR23","doi-asserted-by":"publisher","unstructured":"Chen Y-C, Bazewicz CG, Dinavahi SS, Huntington ND, Schell TD, Robertson GP Emerging role of the p53 pathway in modulating natural killer cell mediated immunity. Mol Cancer Ther [Internet]. 2024; Available from: https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0325.","DOI":"10.1158\/1535-7163.MCT-24-0325"},{"key":"1297_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/15384047.2017.1360446","volume":"19","author":"OF Kuzu","year":"2018","unstructured":"Kuzu OF, Gowda R, Sharma A, Noory MA, Kardos G, Madhunapantula SV, et al. Identification of WEE1 as a target to make AKT inhibition more effective in melanoma. Cancer Biol Ther. 2018;19:53\u201362.","journal-title":"Cancer Biol Ther"},{"key":"1297_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19:723\u201332.","journal-title":"Nat Immunol"},{"key":"1297_CR26","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/ni1138","volume":"5","author":"A Mart\u00edn-Fontecha","year":"2004","unstructured":"Mart\u00edn-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5:1260\u20135.","journal-title":"Nat Immunol"},{"key":"1297_CR27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","volume":"6","author":"A-ME Br\u00f6ske","year":"2022","unstructured":"Br\u00f6ske A-ME, Korfi K, Belousov A, Wilson S, Ooi C-H, Bolen CR, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma. Blood Adv. 2022;6:1025\u201337.","journal-title":"Blood Adv"},{"key":"1297_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/imr.12393","volume":"270","author":"M Klinger","year":"2016","unstructured":"Klinger M, Benjamin J, Kischel R, Stienen S, Zugmaier G. Harnessing T cells to fight cancer with BiTE\u00ae antibody constructs\u2013past developments and future directions. Immunol Rev. 2016;270:193\u2013208.","journal-title":"Immunol Rev"},{"key":"1297_CR29","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1073\/pnas.0730640100","volume":"100","author":"R Castriconi","year":"2003","unstructured":"Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA. 2003;100:4120\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1297_CR30","doi-asserted-by":"publisher","first-page":"6248590","DOI":"10.1155\/2018\/6248590","volume":"2018","author":"B Han","year":"2018","unstructured":"Han B, Mao F-Y, Zhao Y-L, Lv Y-P, Teng Y-S, Duan M, et al. Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res. 2018;2018:6248590.","journal-title":"J Immunol Res"},{"key":"1297_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","volume":"36","author":"SH Ross","year":"2018","unstructured":"Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36:411\u201333.","journal-title":"Annu Rev Immunol"},{"key":"1297_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ni.2936","volume":"15","author":"A Mar\u00e7ais","year":"2014","unstructured":"Mar\u00e7ais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol. 2014;15:749\u201357.","journal-title":"Nat Immunol"},{"key":"1297_CR33","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/d41586-024-01427-4","volume":"629","author":"AB Keener","year":"2024","unstructured":"Keener AB. Natural killer cells show their cancer-fighting worth. Nature. 2024;629:S4\u20136.","journal-title":"Nature"},{"key":"1297_CR34","doi-asserted-by":"publisher","unstructured":"Shemesh A, Pickering H, Roybal KT, Lanier LL Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion. J Exp Med [Internet]. 2022;219. Available from: https:\/\/doi.org\/10.1084\/jem.20212434.","DOI":"10.1084\/jem.20212434"},{"key":"1297_CR35","first-page":"183","volume":"298","author":"SM Vidal","year":"2006","unstructured":"Vidal SM, Lanier LL. NK cell recognition of mouse cytomegalovirus-infected cells. Curr Top Microbiol Immunol. 2006;298:183\u2013206.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1297_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4939-3684-7_15","volume":"1441","author":"SS Somanchi","year":"2016","unstructured":"Somanchi SS, Lee DA. Ex vivo expansion of human NK cells using K562 engineered to express membrane bound IL21. Methods Mol Biol. 2016;1441:175\u201393.","journal-title":"Methods Mol Biol"},{"key":"1297_CR37","doi-asserted-by":"publisher","first-page":"100783","DOI":"10.1016\/j.xcrm.2022.100783","volume":"3","author":"O Demaria","year":"2022","unstructured":"Demaria O, Gauthier L, Vetizou M, Blanchard Alvarez A, Vagne C, Habif G, et al. Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. Cell Rep. Med. 2022;3:100783.","journal-title":"Cell Rep. Med"},{"key":"1297_CR38","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","volume":"25","author":"KC Conlon","year":"2019","unstructured":"Conlon KC, Potter EL, Pittaluga S, Lee C-CR, Miljkovic MD, Fleisher TA, et al. IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion. Clin Cancer Res. 2019;25:4945\u201354.","journal-title":"Clin Cancer Res"},{"key":"1297_CR39","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","volume":"11","author":"TA Waldmann","year":"2020","unstructured":"Waldmann TA, Dubois S, Miljkovic MD, Conlon KC. IL-15 in the combination immunotherapy of cancer. Front Immunol. 2020;11:868.","journal-title":"Front Immunol"},{"key":"1297_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/jir.2018.0019","volume":"39","author":"KC Conlon","year":"2019","unstructured":"Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer. J Interferon Cytokine Res. 2019;39:6\u201321.","journal-title":"J Interferon Cytokine Res"},{"key":"1297_CR41","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18:648\u201359.","journal-title":"Nat Rev Immunol"},{"key":"1297_CR42","doi-asserted-by":"publisher","unstructured":"Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, et al. Data from combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood\u2013derived NK cells facilitates CAR-like responses against CD30+ malignancies [Internet]. 2023. Available from: https:\/\/doi.org\/10.1158\/1078-0432.c.6530711.v1.","DOI":"10.1158\/1078-0432.c.6530711.v1"},{"key":"1297_CR43","doi-asserted-by":"publisher","first-page":"eadn1849","DOI":"10.1126\/sciadv.adn1849","volume":"10","author":"PR Kennedy","year":"2024","unstructured":"Kennedy PR, Arvindam US, Phung SK, Ettestad B, Feng X, Li Y, et al. Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments. Sci Adv. 2024;10:eadn1849.","journal-title":"Sci Adv"},{"key":"1297_CR44","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.4143\/crt.2016.491","volume":"49","author":"JU Schmohl","year":"2017","unstructured":"Schmohl JU, Felices M, Oh F, Lenvik AJ, Lebeau AM, Panyam J, et al. Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity. Cancer Res Treat. 2017;49:1140\u201352.","journal-title":"Cancer Res Treat"},{"key":"1297_CR45","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","volume":"35","author":"US Arvindam","year":"2021","unstructured":"Arvindam US, van Hauten PMM, Schirm D, Schaap N, Hobo W, Blazar BR, et al. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia. 2021;35:1586\u201396.","journal-title":"Leukemia"},{"key":"1297_CR46","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ni.3800","volume":"18","author":"Y Gao","year":"2017","unstructured":"Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017;18:1004.","journal-title":"Nat Immunol"},{"key":"1297_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44789-z","volume":"15","author":"I Dean","year":"2024","unstructured":"Dean I, Lee CYC, Tuong ZK, Li Z, Tibbitt CA, Willis C, et al. Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity. Nat Commun. 2024;15:683.","journal-title":"Nat Commun"},{"key":"1297_CR48","doi-asserted-by":"publisher","first-page":"114333","DOI":"10.1016\/j.celrep.2024.114333","volume":"43","author":"H Sudholz","year":"2024","unstructured":"Sudholz H, Schuster IS, Foroutan M, Sng X, Andoniou CE, Doan A, et al. DOT1L maintains NK cell phenotype and function for optimal tumor control. Cell Rep. 2024;43:114333.","journal-title":"Cell Rep"},{"key":"1297_CR49","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","volume":"131","author":"EM Stein","year":"2018","unstructured":"Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018;131:2661\u20139.","journal-title":"Blood"},{"key":"1297_CR50","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9 J, Sheppard D. TGF-\u03b2 signaling in health and disease. Cell. 2023;186:4007\u201337.","journal-title":"Cell"},{"key":"1297_CR51","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","volume":"18","author":"BC Cho","year":"2023","unstructured":"Cho BC, Lee JS, Wu Y-L, Cicin I, Dols MC, Ahn M-J, et al. Bintrafusp Alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: A randomized, open-label, phase 3 trial. J Thorac Oncol. 2023;18:1731\u201342.","journal-title":"J Thorac Oncol"},{"key":"1297_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/oncolo\/oyac253","volume":"28","author":"F Barlesi","year":"2023","unstructured":"Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J, et al. Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with non-small cell lung cancer resistant or refractory to immune checkpoint inhibitors. Oncologist. 2023;28:258\u201367.","journal-title":"Oncologist"},{"key":"1297_CR53","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamaoncol.2024.2145","volume":"10","author":"M Birrer","year":"2024","unstructured":"Birrer M, Li G, Yunokawa M, Lee J-Y, Kim BG, Oppermann CP, et al. Bintrafusp Alfa for recurrent or metastatic cervical cancer after platinum failure: A nonrandomized controlled trial. JAMA Oncol. 2024;10:1204\u201311.","journal-title":"JAMA Oncol"},{"key":"1297_CR54","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1093\/oncolo\/oyac254","volume":"28","author":"A Spira","year":"2023","unstructured":"Spira A, Wertheim MS, Kim EJ, Tan B, Lenz H-J, Nikolinakos P, et al. Bintrafusp Alfa: A bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with pretreated colorectal cancer: Results from a phase I trial. Oncologist. 2023;28:e124\u20137.","journal-title":"Oncologist"},{"key":"1297_CR55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-021-00809-2","volume":"16","author":"B Tan","year":"2021","unstructured":"Tan B, Khattak A, Felip E, Kelly K, Rich P, Wang D, et al. Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with esophageal adenocarcinoma: Results from a phase 1 cohort. Target Oncol. 2021;16:435\u201346.","journal-title":"Target Oncol"},{"key":"1297_CR56","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41416-024-02677-9","volume":"130","author":"J Kment","year":"2024","unstructured":"Kment J, Newsted D, Young S, Vermeulen MC, Laight BJ, Greer PA, et al. Blockade of TGF-\u03b2 and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses. Br J Cancer. 2024;130:2003\u201315.","journal-title":"Br J Cancer"},{"key":"1297_CR57","doi-asserted-by":"publisher","first-page":"e13854","DOI":"10.1111\/cts.13854","volume":"17","author":"JC Baranda","year":"2024","unstructured":"Baranda JC, Robbrecht D, Sullivan R, Doger B, Santoro A, Barve M, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGF\u03b2 inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1\/1b study. Clin Transl Sci. 2024;17:e13854.","journal-title":"Clin Transl Sci"},{"key":"1297_CR58","doi-asserted-by":"publisher","first-page":"e13736","DOI":"10.1111\/cts.13736","volume":"17","author":"D Robbrecht","year":"2024","unstructured":"Robbrecht D, Grob J-J, Bechter O, Simonelli M, Doger B, Borbath I, et al. Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGF\u03b2) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors. Clin Transl Sci. 2024;17:e13736.","journal-title":"Clin Transl Sci"},{"key":"1297_CR59","doi-asserted-by":"publisher","first-page":"1811605","DOI":"10.1080\/2162402X.2020.1811605","volume":"9","author":"R Greco","year":"2020","unstructured":"Greco R, Qu H, Qu H, Theilhaber J, Shapiro G, Gregory R, et al. Pan-TGF\u03b2 inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. Oncoimmunology. 2020;9:1811605.","journal-title":"Oncoimmunology"},{"key":"1297_CR60","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907\u201313.","journal-title":"JAMA"},{"key":"1297_CR61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-017-0279-5","volume":"5","author":"D Davar","year":"2017","unstructured":"Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, et al. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017;5:74.","journal-title":"J Immunother Cancer"},{"key":"1297_CR62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1172\/JCI6218","volume":"106","author":"TA Fehniger","year":"2000","unstructured":"Fehniger TA, Bluman EM, Porter MM, Mr\u00f3zek E, Cooper MA, VanDeusen JB, et al. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest. 2000;106:117\u201324.","journal-title":"J Clin Invest"},{"key":"1297_CR63","doi-asserted-by":"publisher","first-page":"104539","DOI":"10.1016\/j.ebiom.2023.104539","volume":"90","author":"ME Raeber","year":"2023","unstructured":"Raeber ME, Sahin D, Karakus U, Boyman O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine. 2023;90:104539.","journal-title":"EBioMedicine"},{"key":"1297_CR64","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","volume":"72","author":"WW Overwijk","year":"2021","unstructured":"Overwijk WW, Tagliaferri MA, Zalevsky J. Engineering IL-2 to give New Life to T-cell immunotherapy. Annu Rev Med. 2021;72:281\u2013311.","journal-title":"Annu Rev Med"},{"key":"1297_CR65","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","volume":"22","author":"R Hernandez","year":"2022","unstructured":"Hernandez R, P\u00f5der J, LaPorte KM, Malek TR. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022;22:614\u201328.","journal-title":"Nat Rev Immunol"},{"key":"1297_CR66","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1200\/JCO.23.00172","volume":"41","author":"A Diab","year":"2023","unstructured":"Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA, Larkin J, et al. Bempegaldesleukin plus nivolumab in untreated advanced melanoma: The open-label, phase III PIVOT IO 001 trial results. J Clin Oncol. 2023;41:4756\u201367.","journal-title":"J Clin Oncol"},{"key":"1297_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30874-8","volume":"13","author":"SP D\u2019Angelo","year":"2022","unstructured":"D\u2019Angelo SP, Richards AL, Conley AP, Woo HJ, Dickson MA, Gounder M, et al. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun. 2022;13:3477.","journal-title":"Nat Commun"},{"key":"1297_CR68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.eururo.2022.05.002","volume":"82","author":"AO Siefker-Radtke","year":"2022","unstructured":"Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, et al. Bempegaldesleukin plus nivolumab in first-line metastatic urothelial carcinoma: Results from PIVOT-02. Eur Urol. 2022;82:365\u201373.","journal-title":"Eur Urol"},{"key":"1297_CR69","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/JCO.21.00675","volume":"39","author":"A Diab","year":"2021","unstructured":"Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, et al. Bempegaldesleukin plus nivolumab in first-line metastatic melanoma. J Clin Oncol. 2021;39:2914\u201325.","journal-title":"J Clin Oncol"},{"key":"1297_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14471-1","volume":"11","author":"M Sharma","year":"2020","unstructured":"Sharma M, Khong H, Fa\u2019ak F, Bentebibel S\u2012E, Janssen LME, Chesson BC, et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T-cell-mediated cancer therapy. Nat Commun. 2020;11:661.","journal-title":"Nat Commun"},{"key":"1297_CR71","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/ijc.33382","volume":"148","author":"M Hennessy","year":"2021","unstructured":"Hennessy M, Wahba A, Felix K, Cabrera M, Segura MG, Kundra V, et al. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer. 2021;148:1928\u201337.","journal-title":"Int J Cancer"},{"key":"1297_CR72","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","volume":"610","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto M, Araki K, Cardenas MA, Li P, Jadhav RR, Kissick HT, et al. PD-1 combination therapy with IL-2 modifies CD8+ T-cell exhaustion program. Nature. 2022;610:173\u201381.","journal-title":"Nature"},{"key":"1297_CR73","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","volume":"610","author":"L Codarri Deak","year":"2022","unstructured":"Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature. 2022;610:161\u201372.","journal-title":"Nature"},{"key":"1297_CR74","doi-asserted-by":"publisher","first-page":"101747","DOI":"10.1016\/j.xcrm.2024.101747","volume":"5","author":"J Wu","year":"2024","unstructured":"Wu J, Bloch N, Chang AY, Bhavsar R, Wang Q, Crawford A, et al. A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R\u03b1 strengthens T-cell-mediated anti-tumor therapies. Cell Rep. Med. 2024;5:101747.","journal-title":"Cell Rep. Med"},{"key":"1297_CR75","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","volume":"42","author":"SN Geels","year":"2024","unstructured":"Geels SN, Moshensky A, Sousa RS, Murat C, Bustos MA, Walker BL, et al. Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell. 2024;42:1051\u201366.e7.","journal-title":"Cancer Cell"},{"key":"1297_CR76","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41:450\u201365.","journal-title":"Cancer Cell"},{"key":"1297_CR77","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault M-C, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest. 2018;128:4654\u201368.","journal-title":"J Clin Invest"},{"key":"1297_CR78","doi-asserted-by":"publisher","first-page":"eadp3720","DOI":"10.1126\/sciimmunol.adp3720","volume":"9","author":"O Demaria","year":"2024","unstructured":"Demaria O, Habif G, Vetizou M, Gauthier L, Remark R, Chiossone L, et al. A tetraspecific engager armed with a nonalpha IL-2 variant harnesses natural killer cells against B-cell non-Hodgkin lymphoma. Sci Immunol. 2024;9:eadp3720.","journal-title":"Sci Immunol"},{"key":"1297_CR79","unstructured":"Souza-Fonseca-Guimaraes F, Viel S, Marcais A, Huntington N, Bartholin L, Walzer T, et al. TGF-beta inhibits NK cell activation and cytotoxicity through repression of the mTOR pathway. In: European Journal of Immunology. Wiley-Blackwell 111 River St, Hoboken 07030-5774, NJ USA; 2016. p. 307\u20138."},{"key":"1297_CR80","doi-asserted-by":"publisher","unstructured":"Rautela J, Dagley LF, de Oliveira CC, Schuster IS, Hediyeh-Zadeh S, Delconte RB, et al. Therapeutic blockade of activin-A improves NK cell function and antitumor immunity. Sci Signal [Internet]. 2019;12. Available from: https:\/\/doi.org\/10.1126\/scisignal.aat7527.","DOI":"10.1126\/scisignal.aat7527"},{"key":"1297_CR81","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-21-1052","volume":"10","author":"F Souza-Fonseca-Guimaraes","year":"2022","unstructured":"Souza-Fonseca-Guimaraes F, Rossi GR, Dagley LF, Foroutan M, McCulloch TR, Yousef J, et al. TGF\u03b2 and CIS inhibition overcomes NK-cell suppression to restore antitumor immunity. Cancer Immunol Res. 2022;10:1047\u201354.","journal-title":"Cancer Immunol Res"},{"key":"1297_CR82","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ni.2449","volume":"13","author":"AM Ring","year":"2012","unstructured":"Ring AM, Lin J-X, Feng D, Mitra S, Rickert M, Bowman GR, et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol. 2012;13:1187\u201395.","journal-title":"Nat Immunol"},{"key":"1297_CR83","doi-asserted-by":"publisher","first-page":"1388018","DOI":"10.3389\/fimmu.2024.1388018","volume":"15","author":"N Kim","year":"2024","unstructured":"Kim N, Yi E, Lee E, Park HJ, Kim HS. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression. Front Immunol. 2024;15:1388018.","journal-title":"Front Immunol"},{"key":"1297_CR84","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","volume":"9","author":"MA Salkeni","year":"2023","unstructured":"Salkeni MA, Naing A. Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer. 2023;9:716\u201325.","journal-title":"Trends Cancer"},{"key":"1297_CR85","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1158\/0008-5472.CAN-12-0721","volume":"72","author":"J Emmerich","year":"2012","unstructured":"Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T, et al. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 2012;72:3570\u201381.","journal-title":"Cancer Res"},{"key":"1297_CR86","doi-asserted-by":"publisher","first-page":"619195","DOI":"10.3389\/fimmu.2021.619195","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Guan D, Huo J, Biswas SK, Huang Y, Yang Y, et al. IL-10 enhances human natural killer cell effector functions via metabolic reprogramming regulated by mTORC1 signaling. Front Immunol. 2021;12:619195.","journal-title":"Front Immunol"},{"key":"1297_CR87","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0760-z","volume":"21","author":"K Autio","year":"2019","unstructured":"Autio K, Oft M. Pegylated interleukin-10: Clinical development of an immunoregulatory cytokine for use in cancer therapeutics. Curr Oncol Rep. 2019;21:19.","journal-title":"Curr Oncol Rep"},{"key":"1297_CR88","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","volume":"20","author":"JB Mumm","year":"2011","unstructured":"Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 elicits IFN\u03b3-dependent tumor immune surveillance. Cancer Cell. 2011;20:781\u201396.","journal-title":"Cancer Cell"},{"key":"1297_CR89","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","volume":"34","author":"A Naing","year":"2018","unstructured":"Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, et al. PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T-cell invigoration and polyclonal T-cell expansion in cancer patients. Cancer Cell. 2018;34:775\u201391.e3.","journal-title":"Cancer Cell"},{"key":"1297_CR90","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/S1470-2045(19)30514-5","volume":"20","author":"A Naing","year":"2019","unstructured":"Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumors (IVY): a multicenter, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019;20:1544\u201355.","journal-title":"Lancet Oncol"},{"key":"1297_CR91","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","volume":"34","author":"A Naing","year":"2016","unstructured":"Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, et al. Safety, antitumor activity, and immune activation of pegylated recombinant human Interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol. 2016;34:3562\u20139.","journal-title":"J Clin Oncol"},{"key":"1297_CR92","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10059-011-1057-8","volume":"32","author":"JY Park","year":"2011","unstructured":"Park JY, Lee SH, Yoon S-R, Park Y-J, Jung H, Kim T-D, et al. IL-15-induced IL-10 increases the cytolytic activity of human natural killer cells. Mol Cells. 2011;32:265\u201372.","journal-title":"Mol Cells"},{"key":"1297_CR93","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.4049\/jimmunol.1101021","volume":"187","author":"MA Stacey","year":"2011","unstructured":"Stacey MA, Marsden M, Wang ECY, Wilkinson GWG, Humphreys IR. IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection. J Immunol. 2011;187:2944\u201352.","journal-title":"J Immunol"},{"key":"1297_CR94","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.4049\/jimmunol.2001131","volume":"206","author":"IJ Jensen","year":"2021","unstructured":"Jensen IJ, McGonagill PW, Butler NS, Harty JT, Griffith TS, Badovinac VP. NK cell-derived IL-10 supports host survival during sepsis. J Immunol. 2021;206:1171\u201380.","journal-title":"J Immunol"},{"key":"1297_CR95","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.celrep.2018.04.106","volume":"23","author":"SE Clark","year":"2018","unstructured":"Clark SE, Schmidt RL, McDermott DS, Lenz LL. A Batf3\/Nlrp3\/IL-18 axis promotes natural killer cell IL-10 production during Listeria monocytogenes infection. Cell Rep. 2018;23:2582\u201394.","journal-title":"Cell Rep."},{"key":"1297_CR96","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.4049\/jimmunol.160.6.2637","volume":"160","author":"PT Mehrotra","year":"1998","unstructured":"Mehrotra PT, Donnelly RP, Wong S, Kanegane H, Geremew A, Mostowski HS, et al. Production of IL-10 by human natural killer cells stimulated with IL-2 and\/or IL-12. J Immunol. 1998;160:2637\u201344.","journal-title":"J Immunol"},{"key":"1297_CR97","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/biom12010004","volume":"12","author":"I Martinez-Espinosa","year":"2021","unstructured":"Martinez-Espinosa I, Serrato JA, Ortiz-Quintero B. Role of IL-10-producing natural killer cells in the regulatory mechanisms of inflammation during systemic infection. Biomolecules. 2021;12:4.","journal-title":"Biomolecules"},{"key":"1297_CR98","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.chom.2009.11.003","volume":"6","author":"G Perona-Wright","year":"2009","unstructured":"Perona-Wright G, Mohrs K, Szaba FM, Kummer LW, Madan R, Karp CL, et al. Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe. 2009;6:503\u201312.","journal-title":"Cell Host Microbe"},{"key":"1297_CR99","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","volume":"222","author":"MA Cheever","year":"2008","unstructured":"Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 2008;222:357\u201368.","journal-title":"Immunol Rev"},{"key":"1297_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2016.10.004","volume":"44","author":"J Rautela","year":"2017","unstructured":"Rautela J, Huntington ND. IL-15 signaling in NK cell cancer immunotherapy. Curr Opin Immunol. 2017;44:1\u20136.","journal-title":"Curr Opin Immunol"},{"key":"1297_CR101","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma S, Caligiuri MA, Yu J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol. 2022;43:833\u201347.","journal-title":"Trends Immunol"},{"key":"1297_CR102","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"1297_CR103","doi-asserted-by":"publisher","first-page":"1218082","DOI":"10.3389\/fimmu.2023.1218082","volume":"14","author":"Y Fu","year":"2023","unstructured":"Fu Y, Tang R, Zhao X. Engineering cytokines for cancer immunotherapy: a systematic review. Front Immunol. 2023;14:1218082.","journal-title":"Front Immunol"},{"key":"1297_CR104","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-024-02060-1","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Nogapendekin alfa inbakicept: First approval. Drugs. 2024;84:867\u201374.","journal-title":"Drugs"},{"key":"1297_CR105","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/UPJ.0000000000000517","volume":"11","author":"K Chamie","year":"2024","unstructured":"Chamie K, Chang SS, Kramolowsky EV, Gonzalgo ML, Huang M, Bhar P, et al. Quality of life in the phase 2\/3 trial of N-803 plus Bacillus calmette-Gu\u00e9rin in Bacillus calmette-Gu\u00e9rin\u2012unresponsive nonmuscle-invasive bladder cancer. Urol Pr. 2024;11:367\u201375.","journal-title":"Urol Pr"},{"key":"1297_CR106","doi-asserted-by":"publisher","first-page":"e0298240","DOI":"10.1371\/journal.pone.0298240","volume":"19","author":"C Ji","year":"2024","unstructured":"Ji C, Kuang B, Buetow BS, Vitsky A, Xu Y, Huang T-H, et al. Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys. PLoS One. 2024;19:e0298240.","journal-title":"PLoS One"},{"key":"1297_CR107","doi-asserted-by":"publisher","unstructured":"Shen J, Zou Z, Guo J, Cai Y, Xue D, Liang Y, et al. An engineered concealed IL-15-R elicits tumor-specific CD8+T-cell responses through PD-1-cis delivery. J Exp Med [Internet]. 2022;219. Available from: https:\/\/doi.org\/10.1084\/jem.20220745.","DOI":"10.1084\/jem.20220745"},{"key":"1297_CR108","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-21-0058","volume":"9","author":"Y Xu","year":"2021","unstructured":"Xu Y, Carrascosa LC, Yeung YA, Chu ML-H, Yang W, Djuretic I, et al. An engineered IL15 cytokine mutein fused to an anti-PD1 improves intratumoral T-cell function and antitumor immunity. Cancer Immunol Res. 2021;9:1141\u201357.","journal-title":"Cancer Immunol Res"},{"key":"1297_CR109","doi-asserted-by":"publisher","first-page":"101531","DOI":"10.1016\/j.xcrm.2024.101531","volume":"5","author":"W Shi","year":"2024","unstructured":"Shi W, Liu N, Liu Z, Yang Y, Zeng Q, Wang Y, et al. Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell Rep. Med. 2024;5:101531.","journal-title":"Cell Rep. Med"},{"key":"1297_CR110","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ni.3470","volume":"17","author":"RB Delconte","year":"2016","unstructured":"Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, et al. CIS is a potent checkpoint in NK cell\u2013mediated tumor immunity. Nat Immunol. 2016;17:816.","journal-title":"Nat Immunol"},{"key":"1297_CR111","doi-asserted-by":"publisher","unstructured":"Bernard P-L, Delconte R, Pastor S, Laletin V, Costa Da Silva C, Goubard A, et al. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. J Immunother Cancer [Internet]. 2022;10. Available from: https:\/\/doi.org\/10.1136\/jitc-2021-004244.","DOI":"10.1136\/jitc-2021-004244"},{"key":"1297_CR112","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fimmu.2020.00075","volume":"11","author":"RB Delconte","year":"2020","unstructured":"Delconte RB, Guittard G, Goh W, Hediyeh-Zadeh S, Hennessy RJ, Rautela J, et al. NK Cell Priming From Endogenous Homeostatic Signals Is Modulated by CIS. Front Immunol. 2020;11:75.","journal-title":"Front Immunol"},{"key":"1297_CR113","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41590-023-01718-4","volume":"25","author":"W Goh","year":"2024","unstructured":"Goh W, Sudholz H, Foroutan M, Scheer S, Pfefferle A, Delconte RB, et al. IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development. Nat Immunol. 2024;25:240\u201355.","journal-title":"Nat Immunol"},{"key":"1297_CR114","doi-asserted-by":"publisher","unstructured":"Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood [Internet]. 2020; Available from: https:\/\/doi.org\/10.1182\/blood.2020007748.","DOI":"10.1182\/blood.2020007748"},{"key":"1297_CR115","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jlb.2ma0620-074r","volume":"108","author":"J Rautela","year":"2020","unstructured":"Rautela J, Surgenor E, Huntington ND. Drug target validation in primary human natural killer cells using CRISPR RNP [Internet]. Journal Leukoc Biol. 2020;108:1397\u2013408. https:\/\/doi.org\/10.1002\/jlb.2ma0620-074r. Available from.","journal-title":"Journal Leukoc Biol"},{"key":"1297_CR116","doi-asserted-by":"publisher","unstructured":"Baumgartner CK, Ebrahimi-Nik H, Iracheta-Vellve A, Hamel KM, Olander KE, Davis TGR, et al. The PTPN2\/PTPN1 inhibitor ABBV-CLS-484 unleashes potent antitumor immunity. Nature [Internet]. 2023; Available from: https:\/\/doi.org\/10.1038\/s41586-023-06575-7.","DOI":"10.1038\/s41586-023-06575-7"},{"key":"1297_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40170-8","volume":"14","author":"S Liang","year":"2023","unstructured":"Liang S, Tran E, Du X, Dong J, Sudholz H, Chen H, et al. A small molecule inhibitor of PTP1B and PTPN2 enhances T-cell anti-tumor immunity. Nat Commun. 2023;14:4524.","journal-title":"Nat Commun"},{"key":"1297_CR118","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02404-7","volume":"41","author":"AM Kim","year":"2024","unstructured":"Kim AM, Zhao L, Patel TR, Bailey CJ, Bai Q, Wakefield MR, et al. From bench to bedside: the past, present and future of IL-21 immunotherapy. Med Oncol. 2024;41:181.","journal-title":"Med Oncol"},{"key":"1297_CR119","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","volume":"42","author":"M Shanley","year":"2024","unstructured":"Shanley M, Daher M, Dou J, Li S, Basar R, Rafei H, et al. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell. 2024;42:1450\u201366.e11.","journal-title":"Cancer Cell"},{"key":"1297_CR120","doi-asserted-by":"publisher","first-page":"156787","DOI":"10.1016\/j.cyto.2024.156787","volume":"184","author":"Y Wu","year":"2024","unstructured":"Wu Y, Jiao J, Wu S, Jiang J. Strategies for the enhancement of IL-21 mediated antitumor activity in solid tumors. Cytokine. 2024;184:156787.","journal-title":"Cytokine"},{"key":"1297_CR121","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3389\/fimmu.2020.00832","volume":"11","author":"S Shen","year":"2020","unstructured":"Shen S, Sckisel G, Sahoo A, Lalani A, Otter DD, Pearson J, et al. Engineered IL-21 cytokine muteins fused to anti-PD-1 antibodies can improve CD8+ T-cell function and anti-tumor immunity. Front Immunol. 2020;11:832.","journal-title":"Front Immunol"},{"key":"1297_CR122","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00262-024-03765-8","volume":"73","author":"N Shrestha","year":"2024","unstructured":"Shrestha N, Dee MJ, Chaturvedi P, Leclerc GM, Mathyer M, Dufour C, et al. A \u201cPrime and Expand\u201d strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy. Cancer Immunol Immunother. 2024;73:179.","journal-title":"Cancer Immunol Immunother"},{"key":"1297_CR123","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1158\/1078-0432.CCR-08-2663","volume":"15","author":"ID Davis","year":"2009","unstructured":"Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009;15:2123\u20139.","journal-title":"Clin Cancer Res"},{"key":"1297_CR124","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/bjc.2011.599","volume":"106","author":"N Steele","year":"2012","unstructured":"Steele N, Anthony A, Saunders M, Esmarck B, Ehrnrooth E, Kristjansen PEG, et al. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer. 2012;106:793\u20138.","journal-title":"Br J Cancer"},{"key":"1297_CR125","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1200\/JCO.2007.14.5193","volume":"26","author":"JA Thompson","year":"2008","unstructured":"Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol. 2008;26:2034\u20139.","journal-title":"J Clin Oncol"},{"key":"1297_CR126","doi-asserted-by":"publisher","first-page":"1369743","DOI":"10.3389\/fimmu.2024.1369743","volume":"15","author":"G Isvoranu","year":"2024","unstructured":"Isvoranu G, Chiritoiu-Butnaru M. Therapeutic potential of interleukin-21 in cancer. Front Immunol. 2024;15:1369743.","journal-title":"Front Immunol"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01297-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01297-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01297-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T22:03:30Z","timestamp":1751234610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01297-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":126,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1038\/s41423-025-01297-4","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The NDH reports stock or other ownership in oNKo-Innate and serves on an advisory board for Bristol Myers Squibb, MD Anderson Cancer Centre (Centre for Cell Therapy Innovations) and Syena.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}